Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned
- 1 May 2018
- journal article
- review article
- Published by Elsevier in The Lancet Neurology
- Vol. 17 (5) , 467-480
Abstract
No abstract availableKeywords
This publication has 105 references indexed in Scilit:
- JC Viremia in Natalizumab-Treated Patients with Multiple SclerosisNew England Journal of Medicine, 2013
- Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MSNeurology, 2011
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Predictive factors for prolonged survival in acquired immunodeficiency syndrome—associated progressive multifocal leukoencephalopathyAnnals of Neurology, 1998
- The JC virus antibody response in serum and cerebrospinal fluid in progressive multifocal leucoencephalopathyClinical and Diagnostic Virology, 1995
- Involvement of JC Virus–Infected Mononuclear Cells from the Bone Marrow and Spleen in the Pathogenesis of Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 1988
- CULTIVATION OF PAPOVA-LIKE VIRUS FROM HUMAN BRAIN WITH PROGRESSIVE MULTIFOCAL LEUCOENCEPHALOPATHYThe Lancet, 1971